换一批
换一批Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
第一作者：
Daniel,Shepshelovich
第一单位：
Daniel Shepshelovich, Hadar Goldvaser, and Eitan Amir, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Daniel Shepshelovich and Hadar Goldvaser, Tel-Aviv University, Tel Aviv, Israel; Ariadna Tibau and Consolación Molto, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona; Alberto Ocana, Castilla La Mancha University, Albacete, Spain; and Bostjan Seruga, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
作者：
主题词
抗肿瘤药(Antineoplastic Agents);药物批准(Drug Approval);药物标签(Drug Labeling);人类(Humans);肿瘤(Neoplasms);产品监测, 售后(Product Surveillance, Postmarketing);随机对照试验(主题)(Randomized Controlled Trials as Topic);美国(United States);美国食品和药物管理局(United States Food and Drug Administration)
DOI
10.1200/JCO.2017.77.5593
PMID
29641296
发布时间
2019-08-12
- 浏览4
Journal of clinical oncology
1798-1804页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
